Abstract |
The orphan nuclear receptor COUP-TFII is expressed at a low level in adult tissues, but its expression is increased and shown to promote progression of multiple diseases, including prostate cancer, heart failure, and muscular dystrophy. Suppression of COUP-TFII slows disease progression, making it an intriguing therapeutic target. Here, we identified a potent and specific COUP-TFII inhibitor through high-throughput screening. The inhibitor specifically suppressed COUP-TFII activity to regulate its target genes. Mechanistically, the inhibitor directly bound to the COUP-TFII ligand-binding domain and disrupted COUP-TFII interaction with transcription regulators, including FOXA1, thus repressing COUP-TFII activity on target gene regulation. Through blocking COUP-TFII's oncogenic activity in prostate cancer, the inhibitor efficiently exerted a potent antitumor effect in xenograft mouse models and patient-derived xenograft models. Our study identified a potent and specific COUP-TFII inhibitor that may be useful for the treatment of prostate cancer and possibly other diseases.
|
Authors | Leiming Wang, Chiang-Min Cheng, Jun Qin, Mafei Xu, Chung-Yang Kao, Jingjing Shi, Erli You, Wanchun Gong, Laura Pedro Rosa, Peter Chase, Louis Scampavia, Franck Madoux, Timothy Spicer, Peter Hodder, H Eric Xu, Sophia Y Tsai, Ming-Jer Tsai |
Journal | Science advances
(Sci Adv)
Vol. 6
Issue 18
Pg. eaaz8031
(05 2020)
ISSN: 2375-2548 [Electronic] United States |
PMID | 32494682
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). |
Chemical References |
- COUP Transcription Factor II
- Orphan Nuclear Receptors
|
Topics |
- Animals
- COUP Transcription Factor II
(metabolism)
- Carcinogenesis
- Gene Expression Regulation
- Humans
- Male
- Mice
- Orphan Nuclear Receptors
(genetics, metabolism)
- Prostatic Neoplasms
(drug therapy, genetics)
|